By the Proco Research Team
"Omega-3 is good for your heart" is one of the least controversial claims in supplements — and, looked at closely, one of the more contested ones in the actual trial literature. Two major, recent, high-quality reviews looked at the same broad evidence base and landed in genuinely different places. The reason isn't sloppy science on either side. It's that the underlying randomized trials themselves disagree, sometimes sharply, and the two reviews simply weighted that disagreement differently. Here's the whole picture, honestly.
The skeptical case
A 2020 Cochrane review — generally considered the most rigorous standard in evidence synthesis — pooled 86 randomized trials in 162,796 participants, 28 of them at low summary risk of bias.1 Its conclusion: long-chain omega-3 supplements make little if any difference to most outcomes. On all-cause mortality the evidence was high-certainty and essentially flat (risk ratio 0.97, 95% CI 0.93 to 1.01, from 11,297 deaths across 45 trials). Cardiovascular events overall were also little or unaffected (RR 0.96, 95% CI 0.92 to 1.01, high-certainty), and stroke showed nothing (RR 1.02, 95% CI 0.94 to 1.12).
Two outcomes did move, and it's worth being precise about them rather than rounding them away in either direction. Cochrane judged that increasing long-chain omega-3 may slightly reduce coronary heart disease events (RR 0.91, 95% CI 0.85 to 0.97; number needed to treat 167) and coronary heart disease mortality (RR 0.90, 95% CI 0.81 to 1.00; number needed to treat 334) — both on low-certainty evidence, which is the review's own grading, not a hedge we've added. On lipids, the review found little or no effect on adiposity, blood pressure or blood lipids generally, with one exception: triglycerides fell by roughly 15%, dose-dependently, on high-certainty evidence. HDL cholesterol was not reduced. If you want the dosing detail behind that triglyceride effect, our omega-3 dosage guide walks through what EPA and DHA amounts the trials actually used.
The more favorable case
A 2019 meta-analysis by Hu, Hu and Manson in the Journal of the American Heart Association pooled 13 randomized trials in 127,477 participants and reached a more positive conclusion.2 In the analysis that excluded REDUCE-IT — the most contested trial in the field, discussed below — marine omega-3 supplementation was associated with significantly lower risk of myocardial infarction (rate ratio 0.92, 95% CI 0.86 to 0.99; p=0.020), CHD death (0.92, 0.86 to 0.98; p=0.014), total CHD (0.95, 0.91 to 0.99; p=0.008), cardiovascular death (0.93, 0.88 to 0.99; p=0.013) and total cardiovascular disease (0.97, 0.94 to 0.99; p=0.015). Stroke showed nothing (1.05, 0.98 to 1.14; p=0.183). Major vascular events fell just short of significance (0.97, 0.94 to 1.00; p=0.058) — a result worth naming as non-significant rather than folding into the positive column.
The paper also ran a dose-response meta-regression. Excluding REDUCE-IT, each additional 1,000mg/day of marine omega-3 was associated with 17% lower risk of total cardiovascular disease (95% CI 4% to 29%) and 17% lower risk of major vascular events (95% CI 3% to 28%). The authors are blunt about how much weight that should carry: their dose-response analysis was "highly exploratory and should be interpreted cautiously," because most included trials clustered around 850mg/day, so "the slope of the regression line was essentially determined by few distinctive doses within a narrow range."2 A separate look at how dose tracks with cognitive aging outcomes runs into much the same problem.
Still, that dose-response thread is worth pulling. A handful of large individual trials sit inside these pooled numbers, and they don't just differ in magnitude — they point in different directions entirely. To understand why the two reviews disagree, it helps to look at the three trials that did the most to shape them.
Three trials, three different answers
REDUCE-IT, VITAL, and STRENGTH are the three largest, most-discussed cardiovascular outcome trials of the last decade, and they're the reason omega-3's reputation is so split. All three were large, well-run, randomized, and published in major journals — and they reached three different conclusions.
| Trial | Formulation & dose | Comparator & result |
|---|---|---|
| REDUCE-IT (2019) | Purified EPA (icosapent ethyl), 4,000mg/day | Mineral oil placebo — 25% relative risk reduction in major CV events (HR 0.75)3 |
| VITAL (2019) | Mixed EPA+DHA, ~840mg/day, healthy adults | Olive oil placebo — no significant reduction in major CV events (HR 0.92)4 |
| STRENGTH (2020) | Mixed EPA+DHA (carboxylic acid), 4,000mg/day | Corn oil placebo — no benefit (12.0% vs 12.2%), stopped early for futility5 |
Only REDUCE-IT was positive, and it differs from the other two in two ways at once: it used a purified, EPA-only formulation rather than a mixed EPA/DHA one, and it used a mineral oil placebo rather than a vegetable oil. Which of those two differences actually explains the result is a real, unresolved argument in cardiology — and it matters, because Proco's Omega-3 (and most fish oil supplements) are mixed EPA+DHA formulations, not purified EPA at prescription doses.
The placebo problem
An editorial in Circulation by Bostrom, Beckman and Berger directly questioned whether REDUCE-IT's result reflected the drug doing good or the placebo doing harm.6 The argument: mineral oil is meant to be inert and unabsorbed, yet in REDUCE-IT's placebo arm LDL cholesterol rose by a statistically significant 10.2% (7.0 mg/dL) by the end of year one, and high-sensitivity C-reactive protein rose significantly too, from a median 2.1 mg/L at baseline to 2.8 mg/L at year two — changes that didn't occur with the corn oil placebo used in STRENGTH.67 If the placebo group's own biomarkers were quietly getting worse, some of the apparent 25% benefit could be the comparator underperforming rather than the drug overperforming. This is the same reason we spend so much time on what a placebo arm actually controls for: the comparator is part of the result, not neutral background.
It isn't a settled question. A separate analysis published in European Heart Journal Supplements examined mineral oil's safety record across some 80 trials and reported that its effects on lipids, inflammatory markers, and drug absorption were inconsistent and generally not statistically or clinically meaningful; it also noted that the 5 mg/dL LDL gap between arms would be expected to raise cardiovascular risk by only 2–3%, nowhere near enough to explain a 25% relative risk reduction.7 Worth knowing who wrote it: the author list includes six employees of Amarin Pharma, which makes icosapent ethyl, and REDUCE-IT's own principal investigator. That doesn't make the analysis wrong — it does mean it isn't an independent referee. REDUCE-IT's investigators argue the difference is the drug, not the placebo, on the grounds that purified EPA has membrane-stabilizing effects a mixed EPA/DHA formulation may partially cancel out. Both explanations remain live in the cardiology literature. Neither one changes the fact that the two trials using ordinary fish-oil formulations closer to what's actually sold as a supplement — VITAL and STRENGTH — found no cardiovascular benefit.
The one trial that showed a large benefit used a prescription-only, purified-EPA drug at 4,000mg/day against a placebo whose own chemistry is still being argued about — not a maintenance-dose fish oil supplement.
Why they disagree — and what it means for a standard dose
It's tempting to explain the whole gap between the two reviews as REDUCE-IT doing the heavy lifting, and that would be too neat. The JAHA meta-analysis's significant reductions in myocardial infarction, CHD death, cardiovascular death and total cardiovascular disease all survived removing REDUCE-IT from the pool — the authors led with that analysis precisely to show the findings didn't depend on it.2 Where REDUCE-IT did change things was the shape of the dose-response curve: including it "substantially changed" the regression slopes and introduced statistically significant heterogeneity, which is why the authors call the dose-response work exploratory. The more durable difference between the two reviews is what each counted as a meaningful effect: Cochrane graded a 9% reduction in coronary heart disease events as low-certainty and framed the overall picture as "little or no effect," while JAHA reported comparable point estimates and framed them as real.
Either way, dose and formulation matter for what you can conclude about an over-the-counter product. Icosapent ethyl is a prescription drug taken at 4,000mg/day of purified EPA — more than twenty times the EPA in a single Proco Omega-3 softgel. One Proco softgel provides 1,000mg of fish oil delivering 180mg EPA and 120mg DHA, both printed on the panel: a maintenance serving aimed at closing a dietary gap, and nowhere near the dose or formulation driving REDUCE-IT's positive signal. It's also worth knowing that the cognitive and mood literatures on omega-3 have their own separate dose thresholds, which don't transfer from the cardiovascular trials. And if you take anticoagulants, read how fish oil interacts with blood thinners before adding anything.
Bottom line
The honest position sits between the two headlines, and inside the trial-level disagreement that produced them: omega-3's cardiovascular case is real but modest at typical supplement doses, absent for stroke in both reviews, largely absent in the two largest trials that used formulations closest to an ordinary supplement, and the strongest positive evidence comes from a purified prescription drug at a dose most people will never take — tested against a placebo whose own effects are still being debated. We'd rather say that plainly than lean on "good for your heart" as an unqualified claim the evidence doesn't fully support at the dose on our label.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Abdelhamid AS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, 2020 (CD003177.pub5). cochrane.org
- Hu Y, Hu FB, Manson JE. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127,477 Participants. Journal of the American Heart Association, 2019;8:e013543. ahajournals.org
- Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). New England Journal of Medicine, 2019. nejm.org
- Manson JE, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL). New England Journal of Medicine, 2019. nejm.org
- Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (STRENGTH). JAMA, 2020. jamanetwork.com
- Bostrom JA, Beckman JA, Berger JS. Summoning STRENGTH to Question the Placebo in REDUCE-IT. Circulation, 2021;144:429–431. ahajournals.org
- Olshansky B, Chung MK, Budoff MJ, Philip S, Jiao L, Doyle RT, Copland C, Giaquinto A, Juliano RA, Bhatt DL. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. European Heart Journal Supplements, 2020;22(Suppl J):J34–J48. academic.oup.com
Related reading: Omega-3 Dosage Guide: EPA, DHA, and What the Research Says and Omega-3 and Cognitive Function: EPA, DHA, and What Dose Actually Matters.
Proco Omega-3 provides 1,000mg fish oil per softgel, delivering 180mg EPA and 120mg DHA. Shop Omega-3 →